Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsors and Collaborators: |
University Health Network, Toronto National Cancer Institute of Canada Young Investigator Award - American Society of Clinical Oncologists Peterborough K.M. Hunter Graduate Studentship |
---|---|
Information provided by: | University Health Network, Toronto |
ClinicalTrials.gov Identifier: | NCT00188331 |
This is a prospective, longitudinal cohort study to evaluate fatigue and cognitive function in patients with colorectal cancer (CRC) treated with chemotherapy, and in patients with the same malignancy, that do not receive chemotherapy. A self-report questionnaire for fatigue (the FACT-F), and validated tests of cognitive function, will be applied at predetermined times before, during and after chemotherapy, to determine the incidence, severity and duration of these symptoms. Comparisons will be made in changes in cognition for individuals, as well as between the chemotherapy and the control group. Mechanisms that might lead to fatigue and/or cognitive decline will be investigated.
Condition | Intervention |
---|---|
Cognition Fatigue Colorectal Neoplasm |
Behavioral: Neuropsychological Testing |
Study Type: | Observational |
Study Design: | Prospective |
Official Title: | Cognitive Function and Fatigue in Cancer Patients After Chemotherapy: A Longitudinal Controlled Study in Patients With Colorectal Cancer |
cytokines, genotyping apoE, EUC, LFTs, sex hormones, coagulation factors
Estimated Enrollment: | 360 |
Study Start Date: | November 2003 |
Groups/Cohorts | Assigned Interventions |
---|---|
1
adjuvant/neoadjuvant chemotherapy
|
Behavioral: Neuropsychological Testing
neuropsychological testing with traditional tests, CANTAB and six elements test as well as questionnaires
|
2
non-chemotherapy group
|
Behavioral: Neuropsychological Testing
neuropsychological testing with traditional tests, CANTAB and six elements test as well as questionnaires
|
3
limited metastatic disease or localised recurrence to receive first line metastatic chemotherapy
|
Behavioral: Neuropsychological Testing
neuropsychological testing with traditional tests, CANTAB and six elements test as well as questionnaires
|
We will undertake a prospective, longitudinal controlled study of fatigue and cognitive function in 120 patients with localized CRC who receive 5FU-based adjuvant chemotherapy. Each patient will be evaluated at baseline and at 6, 12 and 24 months for fatigue (using the FACT-F questionnaire) and for cognitive function, using validated tests: these will comprise both traditional neuropsychological tests and the computerised CANTAB™, a which is less dependent on fluency in English. Results during and after chemotherapy will be compared with the pre-chemotherapy assessment (so that each patient acts as their own control). Since baseline evaluation may be confounded by the recent diagnosis and surgery we will include an independent control group of 120 patients who have undergone surgery for CRC but who do not receive chemotherapy. Patients found to have cognitive change will be offered further comprehensive neuropsychological assessment. We will also evaluate quality of life (QOL) using the FACT-G questionnaire and anxiety and depression using the General Health Questionnaire (GHQ). Blood tests including hormone levels, cytokines, homocysteine, procoagulants and apo-lipoprotein E-є4 allele status will evaluate possible mechanisms. Finally, since chemotherapy for CRC is evolving to include the more toxic drugs oxaliplatin and irinotecan, we will perform a parallel pilot study evaluating pts with early recurrent or metastatic CRC who receive these drugs, using similar methods of evaluation.
Ages Eligible for Study: | 18 Years to 75 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Sampling Method: | Probability Sample |
colorectal cancer patients aged 18-75
Inclusion Criteria:
Exclusion Criteria:
Contact: Janette Vardy, MD | 61297675000 | jvardy@med.usyd.edu.au |
Contact: Ian Tannock, MD | 1416 946 2245 | ian.tannock@uhn.on.ca |
Australia, New South Wales | |
Sydney Cancer Centre | Recruiting |
Sydney, New South Wales, Australia, 2139 | |
Contact: Janette Vardy, MD PhD 61297675000 jvardy@med.usyd.edu.au | |
Principal Investigator: Janette Vardy | |
Canada, Ontario | |
University Health Network | Recruiting |
Toronto, Ontario, Canada, M5G 2M9 | |
Contact: Ian Tannock, MD 1 416 946 2245 ian.tannock@uhn.on.ca | |
Contact: Ian Tannock, MD 1416 946 2245 ian.tannock@uhn.on.ca | |
Principal Investigator: Ian Tannock, MD |
Principal Investigator: | Janette Vardy, MD | Princess Margaret Hospital University of Toronto |
Principal Investigator: | Ian Tannock | Princess Margaret Hospital University of Toronto |
Responsible Party: | ( Ian tannock ) |
Study ID Numbers: | COIT1, NCIC Grant No. #15261 |
Study First Received: | September 9, 2005 |
Last Updated: | April 27, 2009 |
ClinicalTrials.gov Identifier: | NCT00188331 History of Changes |
Health Authority: | Canada: Health Canada |
cognitive function fatigue colorectal cancer chemotherapy cognitive impairment |
Signs and Symptoms Digestive System Diseases Digestive System Neoplasms Fatigue Gastrointestinal Diseases Colonic Diseases |
Gastrointestinal Neoplasms Intestinal Diseases Rectal Diseases Intestinal Neoplasms Colorectal Neoplasms |
Fatigue Digestive System Neoplasms Gastrointestinal Diseases Colonic Diseases Intestinal Diseases Rectal Diseases Intestinal Neoplasms |
Signs and Symptoms Neoplasms Neoplasms by Site Digestive System Diseases Gastrointestinal Neoplasms Colorectal Neoplasms |